A Study to Evaluate ALN-2232 in Participants With Obesity — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study to Evaluate ALN-2232 in Participants With Obesity — Stella

View on ClinicalTrials.gov

Recruiting

Back to Obesity trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

Clinical Trial Site, Montreal

Key details

Phase

Early testing / Safety & dosing

Sponsor

Alnylam Pharmaceuticals

Enrollment target

~156 participants

Started

March 2026

Primary completion

February 2028

Age range

18 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.